Hospitals Face Legal Heat for Healthcare AI Failures

Healthcare AI accountability now belongs in the boardroom, not just the procurement file. Hospitals can buy AI tools, hire vendors, and automate workflows, but they can’t outsource responsibility for patient harm, flawed claims decisions, privacy failures, or misleading communications.

Healthcare organizations have moved past the easy question, whether the technology works in a demo. The harder question is who answers when it fails inside care delivery, according to PYMNTS, which interviewed Alaap Shah of Epstein Becker Green on the fragmented legal exposure facing healthcare AI.

“Self-governance matters because defensibility matters. We have already seen that risk is manifesting with respect to the use of AI technology in the healthcare sector,” Shah told Competition Policy International, a PYMNTS company.

XOOMAR’s view: patients don’t experience AI as a vendor module. They experience it as part of the hospital’s care system. If the hospital’s name is on the portal, the letter, the care plan, or the denial workflow, the hospital owns the trust problem.

Hospitals must own every AI decision made in their name

The dangerous fiction in healthcare AI is that responsibility can be pushed downstream to the software supplier. It can’t. Contracts may define who pays after something goes wrong, but they don’t decide whether a patient got a misleading message, whether a clinician relied on an opaque recommendation, or whether a claims workflow treated people differently.

Shah’s central point is not that healthcare lacks rules. It’s that the rules already exist, even if they weren’t written for AI.

“There are existing bodies of law that, while not passed or promulgated for the reason of AI, are still applicable to AI solutions,” Shah said.

That means privacy, discrimination, consumer protection, contracts, and professional duties still matter. A model does not get a liability holiday because lawmakers haven’t produced a clean AI statute.

The Food and Drug Administration still regulates certain software as a medical device, but Shah called the boundary “still a little murky.” He also warned that a company may push close to that line and later hear from FDA: “Actually, this is something we’d like to regulate.”

That uncertainty should make hospital leaders more cautious, not less.

Clinical AI raises the stakes because errors reach the bedside

AI is already moving into areas PYMNTS identifies as clinical decisions, patient communications, claims administration, and health-data exchange. Those are not harmless back-office experiments. They touch diagnosis, treatment, coverage, and the information patients receive from institutions they trust.

A bad product recommendation wastes money. A bad healthcare recommendation can shape care.

That difference matters legally and morally. Shah points to several risk paths. A patient-facing model that gives different recommendations across demographic groups may create discrimination exposure. A clinical tool that influences a physician’s decision may become relevant in a malpractice case. AI is not replacing healthcare’s liability structure. It is entering it.

Clinicians need more than a dashboard and a vague instruction to “use judgment.” They need clear internal rules for when AI output can be trusted, when it must be challenged, and how that judgment gets documented. Otherwise, the clinician becomes the human shield for a system they may not control.

This is where healthcare AI accountability gets real. If a tool changes the flow of care, the hospital has to know how it works, where it is used, who supervises it, and what happens when staff disagree with it.

Vendor contracts won’t protect patients from opaque healthcare algorithms

Hospitals often do not control the models they deploy. Vendors may hold the system logs, training information, performance data, and technical records. That creates a brutal evidentiary problem: when a tool fails inside a hospital, the hospital may still have to explain what happened.

Shah’s warning is direct.

“To the extent that any events could be logged in the AI processing, that is something that needs to be happening so we can understand how that AI operated and why the input led to the output,” Shah said.

A hospital cannot investigate an adverse event if the relevant record sits behind a vendor wall. A clinician cannot defend an AI-influenced decision if no one can reconstruct the path from input to output.

Contracts still matter. They need logging requirements, preservation obligations, audit rights, and clear rules for access to evidence. But the contract is not the governance system. It is only one piece of it.

Shah also flags a privacy risk hospitals cannot shrug off: de-identification is not a magic eraser.

“It’s a real possibility that AI algorithms could re-identify individuals if sufficient data gets put in, even if de-identified in the first instance,” Shah said.

That is not a narrow technical concern. Healthcare systems trade on trust. If AI can reconnect data that looked anonymous in isolation, hospitals need controls before deployment, not excuses after exposure.

Healthcare AI accountability starts with governance before deployment

The prescription is clear: healthcare AI accountability has to begin before the tool enters the workflow.

PYMNTS reports that organizations need to inventory AI systems, classify them by risk, assign accountable owners, train employees, document controls, and allocate responsibility across vendors. That is the minimum credible starting point. XOOMAR analysis: for high-risk healthcare use, that should look less like software procurement and more like clinical infrastructure approval.

A defensible hospital program should include:

• Inventory: A live record of every AI system in use, including patient-facing, clinical, administrative, and claims-related tools.
• Risk classification: Different controls for low-risk automation versus systems influencing treatment, coverage, or patient communications.
• Named owners: Clear responsibility across legal, compliance, IT, clinical leadership, revenue cycle teams, and patient experience.
• Evidence access: Vendor terms requiring logs, preservation, audit rights, and incident cooperation.
• Bias and privacy controls: Testing and review for differential outcomes and re-identification risk.
• Post-deployment monitoring: Ongoing review, not a one-time approval ceremony.

Readers tracking similar institutional-control questions can see XOOMAR’s coverage of Private Equity Puts NHS Patient Records System in TPG Hands and AI Collaboration Quietly Rewrites Work Before Layoffs. The common thread is not that all automation is bad. It is that organizations cannot let critical decisions drift into systems no one inside can explain.

The strongest defense for hospitals is also the weakest excuse

Hospitals have a fair counterargument. They don’t build most of these models. Many systems are proprietary. Smaller health systems may lack the staff, budget, or technical leverage to audit every model deeply. Vendors, regulators, standards bodies, insurers, and technology companies all carry real obligations here.

That defense deserves respect.

But it does not create an escape hatch. Shared responsibility does not erase the hospital’s duty to decide which tools enter its workflows and how they are supervised. A hospital may not know every parameter inside a model, but it can know where the model is used, what evidence the vendor must preserve, who reviews incidents, and when a tool must be paused.

Shah expects fragmentation to persist.

“I think there’s going to be fragmentation for quite a while,” Shah said.

That sentence should chill any executive waiting for a single clean federal answer. The rulebook may stay messy. The exposure will not wait.

Healthcare leaders need to treat AI accountability as patient safety work

Hospital boards and executives should ask four questions now.

• Where is AI being used across clinical decisions, patient communications, claims administration, and health-data exchange?
• Who owns each system internally?
• Can the organization reconstruct what happened when the system produces a harmful or disputed output?
• Will the hospital pause tools that cannot be explained, monitored, or governed?

Patient-facing policies deserve attention too, especially where AI shapes communications or administrative outcomes. The source material does not establish a specific disclosure rule, but trust will suffer if patients learn only after a dispute that automated systems helped shape what they saw, received, or were denied.

Waiting for a lawsuit, scandal, or regulator to force discipline is a choice. It is also a weak one.

The next phase of healthcare AI will reward institutions that can prove they were careful before failure, not just apologetic after it. The hospital that puts its name on the care must put its name on the AI behind it.

Impact Analysis

• Hospitals remain accountable when AI tools affect patient care, claims, privacy, or communications.
• Existing laws on privacy, discrimination, consumer protection, contracts, and professional duties already apply to healthcare AI.
• AI governance is becoming a board-level risk issue, not just a vendor procurement decision.